{'52WeekChange': 1.2227783,
 'SandP52WeekChange': 0.0644362,
 'address1': '21823 30th Drive SE',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 168.9,
 'askSize': 1000,
 'averageDailyVolume10Day': 847737,
 'averageVolume': 1298604,
 'averageVolume10days': 847737,
 'beta': 1.453221,
 'beta3Year': None,
 'bid': 168.81,
 'bidSize': 800,
 'bookValue': 10.227,
 'category': None,
 'circulatingSupply': None,
 'city': 'Bothell',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 170.73,
 'dayLow': 166.73,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -111.491,
 'enterpriseToRevenue': 29.809,
 'enterpriseValue': 28497954816,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 167.27457,
 'fiftyTwoWeekHigh': 187.99,
 'fiftyTwoWeekLow': 65.44,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 124294004,
 'forwardEps': -0.76,
 'forwardPE': -222.125,
 'fromCurrency': None,
 'fullTimeEmployees': 1605,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'heldPercentInsiders': 0.00794,
 'heldPercentInstitutions': 0.94313,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/seattlegenetics.com',
 'longBusinessSummary': 'Seattle Genetics, Inc., a biotechnology company, '
                        'develops and commercializes therapies for the '
                        'treatment of cancer in the United States and '
                        'internationally. The company markets ADCETRIS, an '
                        'antibody-drug conjugate (ADC) for the treatment of '
                        'patients with Hodgkin lymphoma or CD30-positive '
                        'T-cell lymphomas; and PADCEV, an ADC composed of an '
                        'anti-Nectin-4 monoclonal antibody for the treatment '
                        'of metastatic urothelial cancers. It also develops '
                        'Tucatinib, an investigational oral, small molecule '
                        'TKI for HER2, a growth factor receptor; and Tisotumab '
                        'Vedotin, an ADC composed of a human antibody that '
                        'binds to tissue factor to treat various solid tumors, '
                        'including cervical, ovarian, prostate, and bladder. '
                        'In addition, the company develops ladiratuzumab '
                        'vedotin, an ADC targeting LIV-1 and metastatic '
                        'triple-negative breast cancer; SEA-BCMA, a '
                        'clinical-stage non-fucosylated BCMA-directed antibody '
                        'for patients with relapsed or refractory multiple '
                        'myeloma. Seattle Genetics, Inc. has collaboration '
                        'agreements with Takeda Pharmaceutical Company '
                        'Limited; Agensys, Inc.; Genmab A/S; and biotechnology '
                        'and pharmaceutical companies. Seattle Genetics, Inc. '
                        'was incorporated in 1997 and is headquartered in '
                        'Bothell, Washington.',
 'longName': 'Seattle Genetics, Inc.',
 'market': 'us_market',
 'marketCap': 29222213632,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_34145',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -313723008,
 'nextFiscalYearEnd': 1640908800,
 'open': 169.61,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': -0.26,
 'phone': '425 527 4000',
 'previousClose': 172.9,
 'priceHint': 2,
 'priceToBook': 16.506796,
 'priceToSalesTrailing12Months': 30.566273,
 'profitMargins': -0.32814997,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 170.73,
 'regularMarketDayLow': 166.73,
 'regularMarketOpen': 169.61,
 'regularMarketPreviousClose': 172.9,
 'regularMarketPrice': 169.61,
 'regularMarketVolume': 998986,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 173102000,
 'sharesPercentSharesOut': 0.024300002,
 'sharesShort': 4205766,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 4667007,
 'shortName': 'Seattle Genetics, Inc.',
 'shortPercentOfFloat': 0.077199996,
 'shortRatio': 3.37,
 'startDate': None,
 'state': 'WA',
 'strikePrice': None,
 'symbol': 'SGEN',
 'threeYearAverageReturn': None,
 'toCurrency': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -1.863,
 'twoHundredDayAverage': 135.98662,
 'volume': 998986,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.seattlegenetics.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '98021'}